A recent post‐hoc analysis of the BIOSTAT‐CHF study found for women the primary outcome of time to all‐cause mortality or HF‐related hospitalisation was lowest at 50% of the guideline‐recommended angiotensin‐converting enzyme (ACE) inhibitor and beta‐blocker dose, with no further decrease in risk at higher dosages.31 This evidence concerns the gene ACE and hydrops fetalis.